What Коргликард Treats: Main Uses and Benefits

Коргликард is considered relevant for symptomatic support in contexts involving heightened systemic burden, such as acute cardiovascular presentations, specifically in conditions where functional stability becomes affected. The class of cardiac glycosides is relevant across domains where additional symptomatic support is needed for heart failure and rate control.

This medication is primarily used for managing symptoms associated with Systolic Heart Failure (HFrEF) and is relevant for managing symptoms related to heightened physiological activity associated with specific supraventricular arrhythmias, including Atrial Fibrillation and Atrial Flutter. It helps address symptom clusters that may become intense or disruptive, focusing on manifestations like fatigue, weakness, shortness of breath, and fluid retention.

“The primary supportive benefit is realized by easing the overall symptom load associated with compromised heart function, such as difficulty breathing and swelling.”

This support is applied in clinical settings that involve acute or unstable symptom patterns, helping patients cope more steadily with symptom fluctuations and contributing to improved day-to-day comfort. Supportive relief is provided to help maintain a sense of stability when these symptoms become more noticeable.

Quick Fact: Relief for Congestive Symptoms

Regulatory References

1. NIH StatPearls overview of cardiac glycoside therapeutic uses

Who Can and Cannot Use Коргликард?

The drug Коргликард (Corglycard) is primarily registered in the Russian Federation and surrounding regions, and its eligibility profile is based on the official governmental prescribing information from those authorities.

Absolute Exclusions (Contraindications)

Use is strictly prohibited in individuals with the following conditions:

• Hypersensitivity to Corglycon or other cardiac glycosides.
• Acute cardiac events, including acute myocardial infarction, acute myocarditis, or acute endocarditis.
• Severe conduction abnormalities, such as advanced Atrioventricular (AV) block (Grade II–III), severe bradycardia, or Ventricular Tachycardia.
• Specific electrical pathways like Wolff-Parkinson-White (WPW) syndrome.
• Prior toxicity or intoxication with cardiac glycosides.
• Severe structural heart defects, including severe aortic stenosis or hypertrophic obstructive cardiomyopathy.

Restricted and Conditional Use

Use is permitted only under strict medical supervision and may require dosage adjustments for certain populations:

Interactions with other medicines and products

Official regulatory documents require patients and healthcare providers to understand potential interactions that may affect the safety and efficacy of Коргликард. These interactions are categorized based on their mechanism and resulting clinical constraint.

Documented Interaction Domains

• Pharmacodynamic Interactions (Additive Effects): Co-administration with other agents that slow the heart rate or atrioventricular (AV) conduction, such as beta-blockers, certain calcium channel blockers (e.g., Verapamil, Diltiazem), and antiarrhythmics, increases the risk of severe bradycardia and AV block.
• Pharmacokinetic Interactions (Exposure Modification): Substances that inhibit drug-metabolizing enzymes (e.g., Amiodarone, Quinidine) or transporters (P-gp) may significantly increase plasma concentrations, raising the risk of toxicity. Conversely, inducers (e.g., Rifampicin, St. John's Wort) may decrease exposure, potentially reducing therapeutic effect.
• Electrolyte-Dependent Interactions: Medicines that cause the depletion of potassium ( K^+) or magnesium ( Mg^2+), such as potassium-wasting diuretics or corticosteroids, can sensitize the myocardium to the toxic effects of Коргликард, even when drug concentrations are within the accepted range.

Regulatory Constraints and Monitoring

Administration may require spacing in time (e.g., 2 hours) from substances like bile acid sequestrants or antacids to prevent reduced absorption. Due to these interactions, regulatory documents often require close monitoring of plasma concentrations, ECG, and electrolyte levels when combining Коргликард with these identified products.

How Коргликард Works: Mechanism of Action

Core Molecular Action: Enhancing Myocardial Contractility

The primary mechanism involves the direct inhibition of the Sodium-Potassium Pump ( Na^+/ K^+- ATPase) in the heart muscle cell membranes. By blocking this ion transporter, the drug increases the concentration of intracellular sodium. This functional change indirectly alters the Sodium-Calcium Exchanger ( NCX) activity, leading to an increase in the amount of calcium ( Ca^2+) available to the contractile proteins. This molecular cascade results in a positive inotropic effect, which is an augmented force of the heart's pumping action.

Autonomic Control of Heart Rate and Conduction

In addition to its cellular action, the drug modulates the autonomic nervous system by stimulating the central vagal nucleus, which increases parasympathetic outflow to the heart. This neural influence acts on the Sinoatrial (SA) and Atrioventricular (AV) nodes to slow the electrical impulse generation and transmission. The result is a negative chronotropic and dromotropic effect: a reduction in the heart's rate and conduction speed.

Mechanistic Constraints: The Role of Potassium

The drug's molecular binding to the Na^+/ K^+- ATPase is subject to competitive constraint by extracellular potassium ( K^+). High levels of K^+ functionally weaken the drug's affinity and reduce its mechanism's effectiveness, while low K^+ levels potentiate its inhibitory action. This competitive balance defines the physiological sensitivity of the drug's mechanism.

How to Use Коргликард

Коргликард is administered exclusively as a solution for intravenous (I.V.) injection and is intended for use within specialized clinical settings. Its administration requires precise procedural steps, including dilution and controlled infusion.

Standard Dosage and Frequency

Administration follows a strict schedule that defines the amount and frequency of use. Adult dosing is specified in milliliters (ml) of the 0.6 mg/ml solution:

Preparation and Procedural Rules

For proper administration, the calculated dose must be diluted immediately before use. Standard procedures involve combining the dose with 10–20 ml of a 20% or 40% Dextrose solution (alternatively, 0.9% Sodium Chloride solution may be used). This diluted solution must then be administered slowly, ensuring the infusion proceeds over a controlled period of 5–6 minutes.

Population-Specific Use

For pediatric patients, specific dosing guidelines based on age are utilized. Children aged 2 to 5 years receive 0.2 ml to 0.5 ml per dose, while children aged 6 to 12 years are administered 0.5 ml to 0.75 ml per dose. These procedural steps govern the short-term use of this medication.

Research Evidence / Overview of Studies for Коргликард

The research evidence for Коргликард (Convallariae Foliorum Glycoside) is largely contextualized within the scientific literature on its pharmacological group, the cardiac glycosides. This classification includes similar, more widely studied compounds like digoxin. The available information helps show what has been observed so far in research settings regarding its use in the cardiovascular system.

Evidence for Use in Symptomatic Heart Failure (HFrEF)

Studies conducted for the cardiac glycoside class have been used in research exploring how symptoms change over time in adults living with chronic systolic heart failure (HFrEF), which is a condition marked by functional limitations. The research examined outcomes related to systemic or functional imbalance, such as the ability to perform physical tasks. Studies also monitored the frequency of events such as hospitalization due to worsening heart failure.

Findings describe patterns observed in the studies related to outcomes reflecting daily functioning or activity level. Research also highlights changes measured during the study period concerning patient-reported outcomes describing perceived discomfort. However, the certainty remains low regarding the direct, large-scale evidence for this specific active ingredient. Evidence quality varies across studies, and long-term effects on survival are not fully established in the major, published regulatory research.

Evidence for Use in Arrhythmia Rate Control

Коргликард was studied for the management of heart rate during specific conditions involving periods of heightened symptoms related to supraventricular arrhythmias, such as atrial fibrillation. The studies focusing on episodes where symptoms become more noticeable primarily involved clinical electrophysiology investigations and pharmacological research. The research explored whether the compound was observed in the context of controlling the heart's ventricular rate.

Research describes how the compound was observed in controlled settings, where studies monitored changes in the heart's conduction system. Findings indicate patterns related to outcomes describing episodic or acute changes in heart rate. Research describes that this observation is consistent with findings for this drug class.

What Is Still Uncertain About Коргликард Research

A key limitation is that much of the high-quality evidence was observed in some studies of related cardiac glycosides, rather than this specific compound. Therefore, results apply only to the populations studied in those original trials, and certainty remains low when extrapolating all findings directly. Comparative evidence is lacking that explores this compound against contemporary standard-of-care treatments for heart failure and arrhythmias.

Key Studies & References

1. Cardiac Glycoside and Digoxin Toxicity (Used to establish narrow therapeutic window and need for monitoring—a key limitation mentioned in the uncertainty section)

Common questions about Коргликард (FAQ)

Q: What should I do if I experience an unusual or severe side effect while on Коргликард?

Official product information includes instructions that if a severe, sudden, or unusual reaction occurs, seeking immediate medical attention or contacting the healthcare provider right away is necessary. It is important for patients to be aware of known serious side effects, but also to recognize reactions that may not be typical. This prompt action supports the safe use of the medication.

Q: Are there any known interactions between Коргликард and alcohol?

Regulatory guidance notes that discussion of alcohol consumption with the prescribing doctor is outlined in the official product information. This is because alcohol can interact with many medications, potentially affecting how the body processes the medicine or increasing the risk of experiencing certain side effects. Consultation with a healthcare provider provides the specific information needed regarding individual health status and medication use.

Official Storage and Disposal Requirements

This section outlines the mandatory storage and handling conditions for Коргликард (Convallariae Foliorum Glycoside) injection, as defined in official regulatory labeling.

Storage conditions are strictly defined to maintain the stability and integrity of the sterile solution. The product must remain protected from freezing and light exposure. All disposal must comply with environmental guidelines for pharmaceutical waste.